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Analysis of treatment strategies utilized in non-intracranial
hemorrhage secondary to oral anticoagulation therapy
Allison Vargas, Pharm.D., Manny Alfonso, Pharm.D., Heidi Clarke, Pharm.D., BCCCP, Erika Dittmar, Pharm.D., BCPS
Baptist Hospital of Miami, Department of Pharmacy; Miami, FL

BACKGROUND
 There are three FDA-approved reversal agents: 4-factor prothrombin
complex concentrates (4F-PCCs, KCentra) for warfarin, idarucizumab
for dabigatran, and andexanet alfa for apixaban and rivaroxaban
 Despite andexanet alfa’s and idarucizumab’s indication, there is
considerable controversy surrounding reversal strategies for the
factor Xa inhibitors due to the limited data and high cost of the
antidote
 Clinicians frequently use non-specific agents such as 4F-PCC off-label
to reverse factor Xa inhibitors based on limited data
 Vitamin K antagonists are associated with a more than a 3-fold
increase in odds of gastrointestinal (GI) bleeding compared with
placebo or control
 Among patients with atrial fibrillation, dabigatran has an increased
rate of GI bleeding relative to warfarin
 Apixaban is associated with significantly lower odds of major GI
bleeding compared to warfarin
 Dabigatran and rivaroxaban may be associated with increased odds
of major GI bleeding

OBJECTIVES



Analyze the safety and efficacy of reversal agents used within
Baptist Hospital of Miami to manage acute non-ICH major bleeds
secondary to oral anticoagulation
Identify opportunities to optimize the management of non-ICH
major bleeds secondary to oral anticoagulation

RESULTS
Baseline Characteristics
Bleed type, n (%):

Survived
44 (86%)

Apixaban
Rivaroxaban
Warfarin
Dabigatran
Indication for Oral Anticoagulation, n (%)

27 (53%)
14 (27%)
8 (16%)
2 (4%)

2 (4%)
5 (10%)

Secondary Outcomes

12

Incidence of thromboembolic events

1

 Study design: Single center, retrospective chart review of patients
admitted within Baptist Hospital of Miami with a major non-ICH
bleed secondary to oral anticoagulation between January 1, 2019 and
December 31, 2020
 Inclusion criteria: Individuals ≥ 18 years old, major non-ICH bleed,
home oral anticoagulant
 Exclusion criteria: Pregnant, ICH bleed
 Primary outcomes: In-hospital mortality
 Secondary outcomes: Treatment strategies used and the percentage
of patients achieving hemostasis within 24 hours, incidence of
thromboembolic events, and length of stay
 Major bleeding was defined as:
 Bleeding in a critical area or organ*
 Fall in hemoglobin of 2g/dL
 Transfusion of 2 or more units of whole blood or red cells
 Hemostasis was defined as:
 Achievement of post-infusion INR <2
 No administration of blood products past 24 hours

Apixaban/Rivaroxaban
Dabigatran
Warfarin

The overall mortality rate was 8% in major non-ICH bleeds
Average length of stay was 12 days
Majority (86%) of the bleeds were GI
Anti-Xa inhibitors were the most common (80%) oral anticoagulants
used, where a majority of patients were taking apixaban (53%)
 26 patients did not receive a reversal agent, and 7 patients only
received supportive care
 13 patients did not achieve hemostasis within 24 hours of bleeding
onset
 1 patient experienced a thromboembolic event due to holding
anticoagulation

Expired

LIMITATIONS





Small sample size
Last administration time of oral anticoagulant was mostly unknown
Baseline hemoglobin not available for all patients
Majority of patients were not scoped to confirm exact location and
severity of bleed
 Difficult to draw conclusions based on comparative data between
patients with different major bleeds of varying severity

4
(8%)
Apixaban (n=3)
Dabigatran (n=1)
Weight-based
PRBC
PRBC
PCC + PRBCs Fixed-dose PCC
Ischemic
Septic
Uncontrolled
Uncontrolled
Stroke
Shock
bleeding
bleeding

Reversal
Strategy
Cause of
Death

n=51

Mean length of stay (days)






47
(92%)

39 (76%)
Atrial Fibrillation
8 (16%)
Venous Thromboembolism
4 (8%)
Other
Concomitant drugs that increase bleeding
29 (57%)
risk, n (%):

METHODS

CONCLUSION

In-hospital Mortality

n=51

GI
Retroperitoneal
Other
Home Oral Anticoagulant, n (%)

Agent

*Critical sites: intraspinal, intraocular, retroperitoneal, intraarticular or pericardial,
or intramuscular with compartment syndrome

RESULTS

Reversal Strategy Used (n)
Fixed-dose PCC
2
1
2

Weight-based PCC
8
3

Vitamin K
2
5

Tranexamic Acid
1
-

FFP
1
1

PRBC
33
1
5

1

PCC + PRBCs + Tranexamic Acid

1

PRBCs + Vitamin K

1

PCC alone
PRBCs + Vitamin K + PCC
PCC + PRBCs
Supportive Care
Blood products alone

2

1
3

Hemostasis
No Hemostasis

2
4

2
6

1
22

 Blood products are the most frequently utilized management
strategy of major non-ICH bleeds
 Decision making regarding ideal management strategy depends on
patient specific factors including oral anticoagulant, hemoglobin,
platelets, INR, and hemodynamic stability
 Prospective studies with larger sample sizes should be conducted to
establish the most appropriate management strategy for major nonICH bleeds
 In general, use of off-label reversal agents is safe and effective
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